Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2000;86:729-736

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haendeler, J.
Right arrow Articles by Berk, B. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haendeler, J.
Right arrow Articles by Berk, B. C.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CALCIUM COMPOUNDS
*CALCIUM, ELEMENTAL
*Genetics Home Reference
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Cell signalling/signal transduction
(Circulation Research. 2000;86:729.)
© 2000 American Heart Association, Inc.


Molecular Medicine

The Third Cytoplasmic Loop of the Angiotensin II Type 1 Receptor Exerts Differential Effects on Extracellular Signal–Regulated Kinase (ERK1/ERK2) and Apoptosis via Ras- and Rap1-Dependent Pathways

Judith Haendeler, Mari Ishida, Laszlo Hunyady, Bradford C. Berk

From the Center for Cardiovascular Research, University of Rochester, Rochester, NY. Present address of M.I. is Department of Clinical Laboratory, Hiroshima University School of Medicine, Japan; present address of L.H. is Department of Physiology, Semmelweis University of Medicine, Budapest, Hungary.

Correspondence to Bradford C. Berk, MD, PhD, Center for Cardiovascular Research, University of Rochester, 601 Elmwood Ave, Box 679, Rochester, NY 14642. E-mail bradford_berk{at}urmc.rochester.edu


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Abstract—The third cytoplasmic loop of the angiotensin (Ang) II type 1 receptor (AT1) is important for receptor coupling to G proteins and activation of downstream events. Therefore, we determined whether specific AT1 sequences were required for kinase activation and inhibition of apoptosis by transfecting wild-type (AT1Rwt) and mutated AT1 into 293 cells. Ang II stimulated a 19.4-fold increase in extracellular signal–regulated kinase (ERK1/ERK2) activity in 293 cells transfected with AT1Rwt. However, in 293 cells that expressed a receptor in which amino acids 221 and 222 were deleted (AT1R[Del221/222]), Ang II–mediated ERK1/ERK2 activation was inhibited by >85%. In contrast, c-Jun NH2-terminal protein kinase (JNK) activation was similar in AT1Rwt- and AT1R(Del221/222)-transfected cells. Activation of ERK1/ERK2 by AT1Rwt was independent of Ca2+, whereas the low level of ERK1/ERK2 activation by AT1R(Del221/222) was completely Ca2+ dependent. Activation of ERK1/ERK2 in AT1Rwt required Ras, whereas AT1R(Del221/222) required Rap1. These results demonstrate the presence of 2 different pathways for ERK1/ERK2 activation by Ang II, which differ in their requirements for Ca2+ and small G proteins (Ras versus Rap1). Furthermore, Ang II prevented serum deprivation–induced apoptosis in cells transfected with AT1Rwt but not AT1R(Del221/222). AKT was only phosphorylated by Ang II in AT1Rwt-transfected cells. Overexpression of constitutively active AKT significantly reduced serum deprivation–induced apoptosis in cells transfected with AT1R(Del221/222). This study shows for the first time a direct link between kinase activation and inhibition of apoptosis dependent on amino acids 221 and 222 in the third cytoplasmic loop of the AT1.


Key Words: angiotensin II • apoptosis • AT1 • kinases


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Angiotensin II (Ang II), an octapeptide pressor hormone, activates cellular events that may contribute to the pathogenesis of cardiovascular disease.1 The physiological actions of Ang II in adults are mediated largely via the Ang II type 1 receptor (AT1).2 AT1 is a G protein–coupled receptor (GPCR). GPCRs share a common basic structure of 7 transmembrane helices connected by alternating cytoplasmic and extracellular loops. Structure-function analysis of the AT1 has revealed important functional domains for signal transduction in the third cytoplasmic loop.3 AT1 couples signaling events via heterotrimeric G proteins, which occurs primarily through the Gq/11 group of G proteins and the third cytoplasmic loop. Recent studies revealed that a synthetic peptide representing the proximal part of the third cytoplasmic loop (residues 216 to 230) was able to activate purified G proteins, whereas a peptide composing the distal loop (residues 229 to 240) had no effect.4 In addition, the third cytoplasmic loop appears to be necessary for Ang II–mediated conformational changes in the AT1 that result in receptor activation.3

Activation of AT1 by Ang II stimulates protein synthesis and cell hypertrophy.5 6 7 Signaling events required for the growth-promoting effects of Ang II downstream of the AT1 include calcium mobilization and stimulation of kinases such as p38, c-Jun NH2-terminal protein kinase (JNK), and extracellular signal–regulated kinase (ERK1/ERK2).7 8 9 10 Furthermore, Ang II signaling through the AT1 also activates phosphatidylinositol 3-kinase (PI3K), which leads to activation of the serine/threonine kinase AKT, also known as protein kinase B (AKT).11 Activation of PI3K and AKT is associated with growth stimulation by Ang II.12 Recent studies have demonstrated the antiapoptotic and promitogenic functions of ERK1/ERK2 and AKT in different cells.13 14 In contrast, JNK is activated by inflammatory cytokines, reactive oxygen species, and Ang II.10 Activation of JNK is associated with proapoptotic effects.15 Therefore, the present study was performed to elucidate the signaling pathways that are dependent on the third cytoplasmic loop of the AT1 and the effect of mutations in the third loop on activation of kinases and inhibition of apoptosis.


*    Materials and Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Materials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Cell Culture, cDNA Constructs, and Transfection
293 cells were maintained in DMEM containing 10% heat-inactivated FBS. The plasmids for the wild-type AT1 (AT1Rwt) and the deletion mutants were subcloned as described previously.16 Dominant-negative RasN17, Rap1N17, and CDC42N17 were generated as described previously.17 18 Plasmid DNAs were transfected into 293 cells using lipofectamine/Plus according to the manufacturer’s protocol. The final amount of transfected DNA for a 60-mm dish was adjusted to 1.3 µg by pcDNA3.1-LacZ.

[Sar,Ile]Ang II Binding to Intact Cells
To determine the expression level and structural integrity of the mutant receptor, the number of Ang II binding sites was determined as described previously.16

Immunoblotting
After incubation with the indicated stimuli, cells were lysed in lysis buffer (in mmol/L, Tris-HCl 20 [pH 7.5], NaCl 150, KCl 2.5, Na3VO4 2, NaF 50, DTT 2, and benzamidine 2) for 20 minutes and scraped off the plates. After removing the cell debris, equal amounts of protein were loaded on SDS-PAGE and then transferred to polyvinylidene difluoride membranes. Immunoblotting was performed with monoclonal antibodies directed against phospho-ERK1/ERK2, phospho-AKT, and phospho-JNK (New England Biolabs); ERK1/ERK2 and AT1 (Santa Cruz Biotechnology); and Ras and Rap1 (Transduction Laboratories). Antibodies were detected by the enhanced chemiluminescence system (Amersham).

Preparation of Recombinant Proteins
The Raf1-RBD- or the RalGDS-RBD-construct was transformed into Escherichia coli D5{alpha}. Protein production was initiated by addition of 1 mmol/L isopropyl ß-D-thiogalactopyranoside to the culture. Fusion proteins were affinity purified on gluthathione Sepharose 4B to obtain glutathione S-transferase (GST)–Raf1-Ras-binding domain (RBD) to isolate RasGTP or GST-RalGDS-RBD to isolate Rap1GTP.

Ras and Rap1 Activation Assays
Cells were lysed in lysis buffer containing 10 mmol/L MgCl2. GST-Raf1-RBD or GST-RalGDS-RBD was added to the supernatant and incubated overnight at 4°C with slight agitation. After washing the beads 3 times with lysis buffer, Laemmli sample buffer was added and samples were resolved on a 12% SDS-PAGE.

JNK Activation Assay
JNK activity was measured with a commercially available kit based on phosphorylation of recombinant c-Jun (New England Biolabs).

Detection of Cell Death
Cells were cotransfected with 0.9 µg of AT1 plasmids and 0.4 µg of pcDNA3.1-LacZ using lipofectamine/Plus (GIBCO-BRL). After a 24-hour incubation, to allow protein expression, apoptosis was induced by serum deprivation for 24 hours. The dishes were centrifuged to pellet-detached cells. Transfected living and apoptotic cells were identified by ß-galactosidase staining. Cells were fixed in 2% formaldehyde/0.2% glutaraldehyde, and ß-galactosidase activity was determined by incubation with 40 µg/mL X-gal for 24 hours at 37°C. The transfection efficiency with 1.3 µg of pcDNA3.1-LacZ was 90±4%, and the efficiency for the cotransfection was 71±5%. For morphological staining of nuclei, cells were stained with DAPI as described previously.19 Cell apoptosis was also measured by terminal deoxynucleotidyltransferase–mediated dUTP nick end labeling (TUNEL) staining and DNA laddering as described previously.20

Statistical Analysis
Data are expressed as mean±SEM from >=3 independent experiments. Statistical analysis was performed with ANOVA followed by modified least significant difference test.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
*Results
down arrowDiscussion
down arrowReferences
 
Effect of Ang II on ERK1/ERK2 Activation in 293 Cells Transfected With AT1Rwt or AT1R(Del221/222)
We investigated the effect of a deletion in the third cytoplasmic loop of the AT1 on ERK1/ERK2 activation by Ang II. A series of experiments supports a critical role for a conserved apolar residue in the third cytoplasmic loop (Leu222) in agonist-induced activation of the AT1 and possibly many other GPCRs.21 There is also a conserved motif in the third cytoplasmic loop (amino acids 221 and 222) present in both AT1 and AT2, and absent in other GPCRs, suggesting important Ang II–specific effects.22 Therefore, we have chosen to determine the effects on Ang II signal transduction of deleting amino acids 221 and 222 in the AT1. We determined that the expression and binding capacity of AT1R(Del221/222) and AT1Rwt for Ang II were equivalent (93±12% for AT1R[Del221/222]) compared with AT1Rwt (data not shown).21 However, coupling to G proteins by AT1R(Del221/222) was altered, because Ang II failed to stimulate phospholipid hydrolysis.21 In the present experiments, AT1Rwt and AT1R(221/222) were transfected into 293 cells, which do not express AT1. Equivalent protein expression was verified by Western blot analysis (Figure 1ADown). To prove that Ang II–induced ERK1/ERK2 activation was due to activation of the AT1, ERK1/ERK2 activation was blocked by preincubation with losartan, an AT1 antagonist (Figure 1BDown).



View larger version (26K):
[in this window]
[in a new window]
 
Figure 1. Effect of Ang II on ERK1/ERK2 activation. A, Equal expression of AT1Rwt and AT1R(Del221/222) in 293 cells (n=3). B, 293 cells were incubated with Ang II (100 nmol/L for every experiment performed) in the presence or absence of losartan (1 µmol/L) for 5 minutes, and ERK1/ERK2 activation was measured (n=3; upper panel). Equal loading of the blot was confirmed by reprobing with an antibody against ERK1/ERK2 (lower panel). C, Time course analysis for ERK1/ERK2 activation by Ang II in AT1Rwt- and AT1R(Del221/222)-transfected cells. Cells were incubated with Ang II for the indicated time points (upper panel). Equal loading was confirmed with an antibody against ERK1/ERK2 (lower panel). D, Densitometric analysis of ERK1/ERK2 activation by Ang II. Extent of ERK1/ERK2 phosphorylation was quantified by scanning densitometry using the NIH Image program and normalized against ERK1/ERK2 protein content (n=3). IB indicates immunoblot.

First, a time course was studied. Stimulation of both AT1Rwt and AT1R(Del221/222) by Ang II caused maximal activation of ERK1/ERK2 at 3 minutes (Figures 1CUp and 1DUp). However, the ERK1/ERK2 activation by Ang II in cells transfected with AT1R(Del221/222) was significantly less than in cells transfected with AT1Rwt (3.0±0.5–fold versus 19.4±3.2–fold, P<0.01).

Effect of Cytoplasmic Ca2+ on Ang II–induced ERK1/ERK2 Activation
Cytoplasmic Ca2+ plays an important role in Ang II–mediated signal transduction.23 24 25 26 To determine the calcium requirement for Ang II–induced ERK1/ERK2 activation in AT1Rwt- and AT1R(Del221/222)-transfected cells, we used BAPTA-AM, a cytoplasmic Ca2+ chelator.24 ERK1/ERK2 activation by Ang II in AT1Rwt-transfected cells was almost completely Ca2+ independent (Figure 2Down). In contrast, ERK1/ERK2 activation in AT1R(Del221/222)-transfected cells was completely Ca2+ dependent. As a positive control, tumor necrosis factor-{alpha} was used (Figure 2Down). These results suggest that 2 different pathways exist for Ang II–induced ERK1/ERK2 activation by the AT1.



View larger version (29K):
[in this window]
[in a new window]
 
Figure 2. Effect of BAPTA-AM on ERK1/ERK2 activation. A, Either AT1Rwt- or AT1R(Del221/222)-transfected cells were preincubated with 30 µmol/L BAPTA-AM or 0.1% DMSO for 30 minutes followed by Ang II or 15 ng/mL tumor necrosis factor-{alpha} (TNF{alpha}) incubation for 5 minutes. ERK1/ERK2 phosphorylation (p-ERK1/2; upper panel) and content (lower panel) were measured by Western blot (n=5). B, Densitometric analysis of ERK1/ERK2 activation by Ang II in AT1Rwt and AT1R(Del221/222)-transfected cells (n=5). *P<0.01 vs Ang II in AT1R(Del221/222)-transfected cells. IB indicates immunoblot.

Effect of Ras and Rap1 on ERK1/ERK2 Activation
To gain further insight into the upstream mechanisms responsible for Ca2+-dependent and -independent ERK1/ERK2 activation, we studied the ability of Ang II to stimulate Ras and Rap1. Previously, it has been shown that Ca2+ seemed to be required for activation of Rap1.27 Ras was activated by Ang II in AT1Rwt-transfected cells (Figure 3ADown) to a magnitude similar to that observed in vascular smooth muscle cells.8 28 However, Ang II failed to stimulate Ras activity in AT1R(Del221/222)-transfected cells (Figure 3ADown). In contrast, Rap1 was activated in AT1R(Del221/222)-transfected cells, but not in AT1Rwt-transfected cells (Figure 3BDown). Chelation of Ca2+ by BAPTA-AM completely abolished Rap1 activation by Ang II in AT1R(Del221/222)-transfected cells (data not shown). Consistent with these differences in activation of small G proteins, cotransfection with RasN17, a dominant-negative mutant of Ras, dramatically inhibited Ang II–induced ERK1/ERK2 activation in AT1Rwt, but not in AT1R(Del 221/222) (Figure 3CDown). Furthermore, cotransfection with Rap1N17, a dominant-negative mutant of Rap1, almost completely abolished ERK1/ERK2 activation in AT1R(Del 221/222) (Figure 3DDown). On the basis of these results, we speculate that the major pathway for ERK1/ERK2 activation by AT1Rwt occurs via Ras activation and, in addition, a minor pathway exists via Rap1 that is independent of amino acids 221 and 222.



View larger version (25K):
[in this window]
[in a new window]
 
Figure 3. Different effects of Ras and Rap1 on ERK1/ERK2 activation. A, Effect of Ras on Ang II–induced ERK1/ERK2 activation in AT1Rwt- or AT1R(Del221/222)-transfected cells. Ras activation was determined using Raf1-RBD-GST (20 µg). Western blots were performed with an antibody against Ras (upper panel). The extent of Ras activation was quantified by scanning densitometry (lower panel) (n=3). *P<0.01 vs control in AT1Rwt-transfected cells. B, Effect of Rap1 on Ang II–induced ERK1/ERK2 activation in AT1Rwt- or AT1R(Del221/222)-transfected cells. Rap1 activation was determined using RalGDSRBD-GST fusion protein (20 µg). Western blots were performed with an antibody against Rap1 (upper panel). The extent of Rap1 activation was quantified by scanning densitometry (lower panel) (n=3). *P<0.01 vs control in AT1R(Del221/222)-transfected cells. C, Effect of RasN17 on ERK1/ERK2 activation by Ang II. Cells were cotransfected with AT1Rwt or AT1R(Del221/222) and LacZ or RasN17. Western blots were performed with antibodies against phosphospecific ERK1/ERK2 (upper panel) or Ras (lower panel). D, Effect of Rap1N17 on ERK1/ERK2 activation by Ang II. IP indicates immunoprecipitation; IB, immunoblot.

Effect of AT1R(Del221/222) on AKT Activation by Ang II
It has previously been shown that Ang II binding to the AT1 stimulated AKT, and AKT activity was required for vascular smooth muscle cell growth.12 Therefore, the effects of AT1R(Del221/222) on Ang II–induced AKT-activation were determined. Ang II activated AKT in cells transfected with AT1Rwt, with peak at 10 minutes. No activation occurred in cells transfected with AT1R(Del221/222) (Figure 4ADown). Preincubation with the PI3K antagonist, LY294002, completely inhibited Ang II–induced AKT activation in AT1Rwt-transfected cells (Figure 4BDown). In contrast, LY294002 did not show any effect on ERK1/ERK2 activation by Ang II (Figure 4BDown).



View larger version (34K):
[in this window]
[in a new window]
 
Figure 4. Activation of AKT by Ang II. A, Effect on Ang II–induced AKT activation in AT1Rwt- or AT1R(Del221/222)-transfected cells. Cells were incubated with Ang II for 10 minutes, and Western blots were performed with an antibody against phosphospecific AKT (p-AKT; residue 473). Membranes were reprobed with an antibody against AKT (upper panel). The extent of AKT phosphorylation was quantified by scanning densitometry (lower panel) (n=3). *P<0.01 vs control in AT1Rwt-transfected cells. B, Effect of LY294002 on Ang II–induced AKT and ERK1/ERK2 activation. Transfected cells were preincubated with LY294002 (10 µmol/L) for 30 minutes, followed by treatment with Ang II for 10 minutes, and Western blots were performed with an antibody against phosphospecific AKT (residue 473). Membranes were then reprobed with anti–phospho-ERK1/ERK2 (n=3). IB indicates immunoblot.

Effect of AT1R(Del221/222) on JNK Activation by Ang II
Although AKT and ERK1/ERK2 are involved in cell growth, JNK, another kinase activated by Ang II, has been suggested to play a role in apoptosis.15 25 Therefore, we examined Ang II–induced JNK activation in cells transfected with AT1R(Del221/222). As expected, JNK was activated by Ang II in AT1Rwt-transfected cells, with a maximal increase at 15 minutes (Figure 5ADown). In AT1R(Del221/222)-transfected cells, JNK was stimulated to a similar magnitude (Figure 5ADown). To determine whether activation of JNK via the AT1Rwt and the AT1R(Del221/222) required the same upstream mediators, we studied the role of CDC42, a known upstream activator of JNK. CDC42N17, a dominant-negative mutant of CDC42, was cotransfected with AT1Rwt or AT1R(Del221/222), and JNK activity was measured.18 Activation of JNK was completely abolished in 293 cells cotransfected with CDC42N17 and AT1Rwt or AT1R(Del221222) (Figure 5BDown). Cells cotransfected with LacZ or RasN17 and AT1Rwt or AT1R(Del221/222) had no effect on Ang II–induced jun phosphorylation (Figure 5BDown).



View larger version (27K):
[in this window]
[in a new window]
 
Figure 5. Effect of Ang II and CDC42N17 on JNK activation. A, Time course of JNK activation in AT1Rwt- and AT1R(Del221/222)-transfected cells. Cells were incubated with Ang II for the indicated times, and the JNK activation assay was performed (upper panel). The extent of Jun phosphorylation was quantified by scanning densitometry (lower panel; n=3). B, Effect of CDC42N17 on Ang II–induced JNK activation. Cells were cotransfected with AT1Rwt or AT1R(Del221/222) and LacZ, CDC42N17, or RasN17 (upper panel). The extent of Jun phosphorylation was quantified by scanning (lower panel) (n=5). *P<0.01 vs LacZ/control in AT1Rwt; **P<0.01 vs Ras/control in AT1Rwt; #P<0.01 vs LacZ/control in AT1R(Del221/222); ##P<0.01 vs Ras/control in AT1R(Del221/222). IP indicates immunoprecipitation; IB, immunoblot.

Effect of Ang II on Serum Deprivation–Induced Apoptosis in AT1Rwt- and AT1R(Del221/222)-Transfected Cells
To gain further insight into the physiological role of amino acids 221 and 222 in the third cytoplasmic loop of the AT1, we examined the effect of Ang II on serum deprivation–induced apoptosis in 293 cells transfected with AT1Rwt or AT1R(Del221/222. Apoptosis was induced by removing serum for 24 hours in the presence or absence of Ang II. Ang II significantly decreased apoptosis induced by serum deprivation in cells transfected with AT1Rwt (Figures 6ADown through 6C). However, in cells transfected with AT1R(Del221/222), Ang II had no effect on apoptosis induction (Figures 6ADown through 6C). To ensure that the morphological changes observed with DAPI staining were due to apoptosis, we also measured apoptosis with TUNEL staining and DNA laddering and obtained results similar to those with DAPI stain (Figure 6BDown and data not shown). To verify that the effect of Ang II on serum deprivation–induced apoptosis was not a nonspecific feature of AT1R(Del221/222)-transfected cells, we determined the ability of thrombin to prevent apoptosis. Serum deprivation–induced apoptosis in AT1Rwt- and AT1R(Del221/222)-transfected cells was significantly inhibited by thrombin to the same extent (Figure 6CDown). Furthermore, we investigated H2O2-induced apoptosis, which was also inhibited by Ang II in AT1Rwt-transfected cells, but not in cells transfected with AT1R(Del221/222) (data not shown).



View larger version (70K):
[in this window]
[in a new window]
 
Figure 6. Signal transduction pathways involved in serum deprivation–induced apoptosis. A, Effect of Ang II on serum deprivation–induced apoptosis. Apoptosis was induced in AT1Rwt- or AT1R(Del221/222)-transfected cells by serum deprivation for 24 hours. Cells were coincubated with Ang II or PBS. After incubation, cells were centrifuged to pellet detached cells and then stained with DAPI. A representative experiment is shown. B, Effect of Ang II on serum deprivation–induced apoptosis. Cells were cultured on coverslips and treated as in panel A. Cells were stained with TUNEL reagent (Roche/Boehringer Mannheim). C, Effect of thrombin on serum deprivation–induced apoptosis. Cells were incubated with either thrombin (2 U/mL) or Ang II (n=5). *P<0.01 vs serum deprivation in AT1Rwt-transfected cells; #P<0.01 vs serum deprivation in AT1R(Del221/222)-transfected cells. D, Effect of PD98059 and LY294002 on serum deprivation–induced apoptosis. Cells were cotransfected with pcDNA3.1-LacZ and AT1Rwt or At1R(Del221/222). Cells were coincubated with Ang II, PD98059 (10 µmol/L), and LY294002 (10 µmol/L) as indicated. Transfected living and apoptotic cells were identified by ß-galactosidase staining (n=5). *P<0.01 vs serum deprivation in AT1Rwt-transfected cells; **P<0.05 vs serum deprivation in AT1Rwt-transfected cells; #P<0.01 vs serum deprivation+Ang II in AT1Rwt-transfected cells.

Because AKT and ERK1/ERK2 are both known to have antiapoptotic functions, and our data demonstrate that AKT- and ERK1/ERK2-activation occur via 2 independent pathways (Figure 4BUp), we used pharmacological inhibitors to determine their relative roles in the antiapoptotic effect of Ang II. The PI3K inhibitor LY294002 blocked the antiapoptotic effect of Ang II in AT1Rwt-transfected cells to a greater extent than the mitogen-activated protein kinase (MEK)/ERK1 inhibitor PD98059 (Figure 6DUp). When used in combination, PD98059 and LY294002 completely abolished the antiapoptotic effect of Ang II in AT1Rwt-transfected cells (Figure 6DUp). In cells transfected with AT1R(Del221/222), the inhibitors showed no effect (Figure 6DUp).

Effect of Constitutively Active AKT on Serum Deprivation–Induced Apoptosis
We further investigated the role of Ang II in the signal transduction pathways dependent on amino acids 221 and 222. We cotransfected constitutively active AKT13 and AT1R(Del221/222) to show that we could rescue cells from serum deprivation–induced apoptosis. Indeed, as shown in Figure 7Down, overexpression of constitutively active AKT significantly inhibited serum deprivation–induced apoptosis in AT1R(Del221/222)-transfected cells (Figure 7Down).



View larger version (12K):
[in this window]
[in a new window]
 
Figure 7. Effect of constitutive active AKT on serum deprivation–induced apoptosis. Cells were cotransfected with constitutively active AKT and AT1R(Del221/222). After apoptosis induction, cells were stained with DAPI (n=4). *P<0.01 vs serum deprivation in AT1R(Del221/222)-transfected cells; #P<0.01 vs serum deprivation+Ang II in AT1R(Del221/222)-transfected cells.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
*Discussion
down arrowReferences
 
In the present study, we demonstrated that binding of Ang II to AT1 activates ERK1/ERK2 via 2 pathways and that activation of ERK1/ERK2 and AKT by Ang II via the third cytoplasmic loop of the AT1 is necessary for serum deprivation–induced apoptosis inhibition (Figure 8Down). The major pathway (as defined by the magnitude of ERK1/ERK2 activation) stimulates Ras, is independent of cytoplasmic Ca2+, and requires the presence of amino acids 221 and 222 in the third cytoplasmic loop, whereas the minor pathway activates Rap1 and is dependent on cytoplasmic Ca2+ and not on amino acids 221 and 222. In contrast, the third cytoplasmic loop is not required for Ang II–mediated activation of CDC42 and the downstream kinase, JNK. Finally, the activation of AKT and ERK1/ERK2 that is dependent on amino acids 221 and 222 in the third cytoplasmic loop is required for Ang II–mediated inhibition of serum deprivation–induced apoptosis. These data provide evidence for the first time that ERK1/ERK2 activation by Ang II occurs via 2 distinct pathways (via Ras and via Rap1), as well as a direct link between activation of several kinases by the third cytoplasmic loop of the AT1 and inhibition of apoptosis by Ang II.



View larger version (18K):
[in this window]
[in a new window]
 
Figure 8. Model for the signaling events induced by Ang II binding to the AT1. The major pathway for the ERK1/ERK2 activation and AKT activation requires amino acids 221 and 222 of the third cytoplasmic loop of the AT1. These pathways are necessary for the apoptosis inhibition by Ang II via the AT1 (AT1R). In contrast, JNK activation via CDC42 and activation of ERK1/ERK2 by Rap1 are independent of amino acids 221 and 222 and not involved in the inhibition of apoptosis.

The "minor" pathway for ERK1/ERK2 activation by the AT1, which requires Rap1 activity and cytoplasmic Ca2+, was revealed by deletion of 2 amino acids (221 and 222) in the third cytoplasmic loop. The fact that Rap1 activation was not observed in cells transfected with AT1Rwt has 2 possible explanations. The most likely explanation is that signals stimulated by Ang II binding to the AT1Rwt inhibit Rap1 activity. A less likely explanation is that the AT1R(Del 221/222) has acquired a novel function (ie, a receptor metamorphosis) that results in altered coupling to downstream mediators. Given that the deletion of amino acids 221 and 222 in the AT1 abolishes phosphoinositide turnover,21 it seems that RAP1 activation requires an ambient level of intracellular calcium. The fact that the 2 AT1-stimulated ERK1/ERK2 pathways are characterized by a difference in their requirement for Ca2+ may provide an explanation for reports that have found varying degrees of calcium dependence for ERK1/ERK2 activation by Ang II in multiple cell types.23 26 29 30 It is possible that differences in the relative expression of the mediators responsible for the 2 pathways identified in the present study may explain these findings. If such differences occurred in vivo, there would be potentially significant physiological effects in tissue responses to Ang II.

Insight into the roles of the 2 AT1-dependent ERK1/ERK2 activation pathways may be derived from consideration of the specific functions of Ras and Rap1. Ras is activated by Grb2 adaptor proteins and the guanine nucleotide exchange factor SOS, whereas Rap1 is activated by CRK adaptor proteins and the guanine-nucleotide-exchange factor C3G. Two 2 nonexclusive roles for Rap1 have been proposed, as follows31 : (1) as a negative regulator of Ras-dependent signal events and (2) as an upstream Ras-like small G protein that couples to downstream kinases.30 32 In support of Rap1 inhibiting Ras are the data of Okada et al,33 which showed a "competition" between Ras and Rap1 for binding to Raf1. These authors showed that insulin stimulation of the human insulin receptor inactivated Rap1 and decreased the amount of Rap1 bound to Raf1, whereas association of Raf1 with Ras was increased. In contrast, Franke et al27 showed in platelets that Rap1 was activated by GPCRs, which required a rise in cytoplasmic Ca2+ and was induced by agents that increase cytoplasmic Ca2+. Finally, York et al32 reported that activation of ERK1/ERK2 by nerve growth factor in PC12 cells required both Ras and Rap1. Initial activation of ERK1/ERK2 required Ras, but sustained ERK1/ERK2 activation required Rap1 via stimulation of the downstream B-Raf/MEK/ERK cascade. Thus, our data provide evidence that in cells expressing both B-Raf and Raf1, Ang II may regulate ERK1/ERK2 via these parallel pathways.

The nature of the interaction between signal mediators and the AT1 third cytoplasmic loop remains undefined. However, it is clear that Ang II binding induces a conformational change in the AT1 that, in the presence of GTP-bound G proteins, confers an additional conformational change to yield a high-affinity state of the receptor.34 Our findings now indicate further that a critical conformational change in the AT1 is mediated by the third cytoplasmic loop. When this interaction is disrupted, alternative pathways such as the Rap1-dependent pathway described in the present study are revealed.

The signaling pathways that determine cell death versus cell survival via the AT1 are poorly understood. It is known that binding of Ang II to the AT1 activates AKT and ERK1/ERK2 and both kinases participate in inhibition of apoptosis. An important physiological property of Ang II is its ability to regulate cell growth and apoptosis.19 35 Recently, it has been found that Ang II can exert both antiapoptotic and proapoptotic effects in a cell- and receptor-specific manner. Binding of Ang II to the AT1 inhibits apoptosis of vascular smooth muscle cells35 and 293 cells (as shown in the present study). In contrast, in endothelial cells, the AT1 promotes apoptosis by activation of caspases via the AT1 as well as via the AT2.19 However, the regulatory mechanisms by which Ang II inhibits apoptosis via the AT1 in smooth muscle cells or other cell lines are poorly defined. Pollman et al35 showed that Ang II inhibited NO-induced apoptosis in vascular smooth muscle cells. Furthermore, it is well known that PI3K, AKT, and ERK1/ERK2 are involved in cell survival and in apoptosis suppression.8 14 Thus, our data for the first time connect the antiapoptotic functions of the AT1 with the activation of kinases AKT and ERK1/ERK2 because of amino acids 221 and 222 of the third cytoplasmic loop of the AT1.

Consistent with our findings that the third cytoplasmic loop is important for G protein coupling are recent studies demonstrating that G proteins play a role in mitogenesis and cell growth.36 Furthermore, JNK, which seems to have a proapoptotic function, is not activated by events dependent on amino acids 221 and 222. The effects of Ang II on growth and apoptosis mediated by ERK1/ERK2, AKT, and JNK in vitro are likely to be important in vivo, as shown by studies in the rat carotid balloon injury model.37 Together with the present study, these results suggest that the AT1 third cytoplasmic loop is critical in determining the nature of Ang II effects on cell growth and apoptosis. Moreover, mutations in the third cytoplasmic loop of the AT1 or alterations in G proteins that couple to the third cytoplasmic loop may be pathogenic in vascular diseases such as hypertension, atherosclerosis, and restenosis after balloon angioplasty.


*    Acknowledgments
 
This study was supported by NIH/National Heart, Lung, and Blood Institute Grants R01HL491921 and HL 59975 (to B.C.B.). J.H. was supported by Deutsche Forschungsgemeinschaft Grant HA 2868/1-1. We thank Dr Shalloway (Cornell University, Ithaca, NY) for providing the Raf-RBD, Dr Meinkoth (University of Pennsylvania, Philadelphia, Pa) for the RalGDS-RBD construct, and Dr S. Dimmeler (University of Frankfurt, Frankfurt, Germany) for the AKT construct.

Received October 13, 1999; accepted January 27, 2000.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
up arrowDiscussion
*References
 

  1. Griendling KK, Ushio F-M, Lassegue B, Alexander RW. Angiotensin II signaling in vascular smooth muscle: new concepts. Hypertension. 1997;29:366–373.[Abstract/Free Full Text]
  2. Oliverio MI, Best CF, Kim HS, Arendshorst WJ, Smithies O, Coffman TM. Angiotensin II responses in AT1A receptor-deficient mice: a role for AT1B receptors in blood pressure regulation. Am J Physiol. 1997;272:F515–F520.[Abstract/Free Full Text]
  3. Franzoni L, Nicastro G, Pertinhez TA, Oliveira E, Nakaie CR, Paiva AC, Schreier S, Spisni A. Structure of two fragments of the third cytoplasmic loop of the rat angiotensin II AT1A receptor: implications with respect to receptor activation and G-protein selection and coupling. J Biol Chem. 1999;274:227–235.[Abstract/Free Full Text]
  4. Sano T, Ohyama K, Yamano Y, Nakagomi Y, Nakazawa S, Kikyo M, Shirai H, Blank JS, Exton JH, Inagami T. A domain for G protein coupling in carboxyl-terminal tail of rat angiotensin II receptor type 1A. J Biol Chem. 1997;272:23631–23636.[Abstract/Free Full Text]
  5. Berk BC, Vekshtein V, Gordon HM, Tsuda T. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension. 1989;13:305–314.[Abstract/Free Full Text]
  6. Geisterfer AAT, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res. 1988;62:749–756.[Abstract/Free Full Text]
  7. Ushio-Fukai M, Alexander RW, Akers M, Griendling KK. p38 mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II: role in vascular smooth muscle cell hypertrophy. J Biol Chem. 1998;273:15022–15029.[Abstract/Free Full Text]
  8. Liao DF, Duff JL, Daum G, Pelech SL, Berk BC. Angiotensin II stimulates MAP kinase kinase kinase activity in vascular smooth muscle cells: role of Raf. Circ Res. 1996;79:1007–1014.[Abstract/Free Full Text]
  9. Duff JL, Berk BC, Corson MA. Angiotensin II stimulates the pp44 and pp42 mitogen-activated protein kinases in cultured rat aortic smooth muscle cells. Biochem Biophys Res Commun. 1992;188:257–264.[Medline] [Order article via Infotrieve]
  10. Schmitz U, Ishida T, Ishida M, Surapisitchat J, Hasham MI, Pelech S, Berk BC. Angiotensin II stimulates p21-activated kinase in vascular smooth muscle cells: role in activation of JNK. Circ Res. 1998;82:1272–1278.[Abstract/Free Full Text]
  11. Takahashi T, Taniguchi T, Konishi H, Kikkawa U, Ishikawa Y, Yokohama M. Activation of AKT/protein kinase B after stimulation with angiotensin II in vascular smooth muscle cells. Am J Physiol. 1999;276:H1927–H1934.[Abstract/Free Full Text]
  12. Saward L, Zahradka P. Angiotensin II activates phosphatidylinositol 3-kinase in vascular smooth muscle cells. Circ Res. 1997;81:249–257.[Abstract/Free Full Text]
  13. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601–605.[Medline] [Order article via Infotrieve]
  14. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell. 1997;88:435–437.[Medline] [Order article via Infotrieve]
  15. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995;270:1326–1331.[Abstract/Free Full Text]
  16. Hunyady L, Baukal AJ, Balla T, Catt KJ. Independence of type I angiotensin II receptor endocytosis from G protein coupling and signal transduction. J Biol Chem. 1994;269:24798–24804.[Abstract/Free Full Text]
  17. de Rooij J, Bos JL. Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene. 1997;14:623–625.[Medline] [Order article via Infotrieve]
  18. Coso OA, Chiariello M, Yu JC, Teramoto H, Crespo P, Xu N, Miki T, Gutkind JS. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell. 1995;81:1137–1146.[Medline] [Order article via Infotrieve]
  19. Dimmeler S, Rippmann V, Weiland U, Haendeler J, Zeiher AM. Angiotensin II induces apoptosis of human endothelial cells: protective effect of nitric oxide. Circ Res. 1997;81:970–976.[Abstract/Free Full Text]
  20. Haendeler J, Messmer UK, Brune B, Neugebauer E, Dimmeler S. Endotoxic shock leads to apoptosis in vivo and reduces Bcl-2. Shock. 1996;6:405–409.[Medline] [Order article via Infotrieve]
  21. Hunyady L, Zhang M, Jagadeesh G, Bor M, Balla T, Catt KJ. Dependence of agonist activation on a conserved apolar residue in the third intracellular loop of the AT1 angiotensin receptor. Proc Natl Acad Sci U S A. 1996;93:10040–10045.[Abstract/Free Full Text]
  22. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem. 1993;268:24539–24542.[Abstract/Free Full Text]
  23. Brinson AE, Harding T, Diliberto PA, He Y, Li X, Hunter D, Herman B, Earp HS, Graves LM. Regulation of a calcium-dependent tyrosine kinase in vascular smooth muscle cells by angiotensin II and platelet-derived growth factor. J Biol Chem. 1998;273:1711–1718.[Abstract/Free Full Text]
  24. Lucchesi PA, Bell JM, Willis LS, Byron KL, Corson MA, Berk BC. Ca2+-dependent mitogen-activated protein kinase activation in spontaneously hypertensive rat vascular smooth muscle defines a hypertensive signal transduction phenotype. Circ Res. 1996;78:962–970.[Abstract/Free Full Text]
  25. Zohn IE, Yu H, Li X, Cox AD, Earp HS. Angiotensin II stimulates calcium-dependent activation of c-Jun N-terminal kinase. Mol Cell Biol. 1995;15:6160–6168.[Abstract]
  26. Eguchi S, Matsumoto T, Motley ED, Utsunomiya H, Inagami T. Identification of an essential signaling cascade for mitogen-activated protein kinase activation by angiotensin II in cultured rat vascular smooth muscle cells: possible requirement of Gq-mediated p21ras activation coupled to a Ca2+/calmodulin-sensitive tyrosine kinase. J Biol Chem. 1996;271:14169–14175.[Abstract/Free Full Text]
  27. Franke B, Akkerman JW, Bos JL. Rapid Ca2+-mediated activation of Rap1 in human platelets. EMBO J. 1997;16:252–259.[Medline] [Order article via Infotrieve]
  28. Okuda M, Kawahara Y, Yokoyama M. Angiotensin II type 1 receptor-mediated activation of Ras in cultured rat vascular smooth muscle cells. Am J Physiol. 1996;271:H595–H601.[Abstract/Free Full Text]
  29. Sayeski PP, Ali MS, Harp JB, Marrero MB, Bernstein KE. Phosphorylation of p130Cas by angiotensin II is dependent on c-Src, intracellular Ca2+, and protein kinase C. Circ Res. 1998;82:1279–1288.[Abstract/Free Full Text]
  30. de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, Bos JL. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature. 1998;396:474–477.[Medline] [Order article via Infotrieve]
  31. Marshall CJ. Taking the Rap. Nature. 1998;392:553–554.[Medline] [Order article via Infotrieve]
  32. York RD, Yao H, Dillon T, Ellig CL, Eckert SP, McCleskey EW, Stork PJ. Rap1 mediates sustained MAP kinase activation induced by nerve growth factor. Nature. 1998;392:622–626.[Medline] [Order article via Infotrieve]
  33. Okada S, Matsuda M, Anafi M, Pawson T, Pessin JE. Insulin regulates the dynamic balance between Ras and Rap1 signaling by coordinating the assembly states of the Grb2-SOS and CrkII-C3G complexes. EMBO J. 1998;17:2554–2565.[Medline] [Order article via Infotrieve]
  34. Wang C, Jayadev S, Escobedo JA. Identification of a domain in the angiotensin II type 1 receptor determining Gq coupling by the use of receptor chimeras. J Biol Chem. 1995;270:16677–16682.[Abstract/Free Full Text]
  35. Pollman MJ, Yamada T, Horiuchi M, Gibbons GH. Vasoactive substances regulate vascular smooth muscle cell apoptosis: countervailing influences of nitric oxide and angiotensin II. Circ Res. 1996;79:748–756.[Abstract/Free Full Text]
  36. Luttrell LM, van Biesen T, Hawes BE, Koch WJ, Touhara K, Lefkowitz RJ. G beta gamma subunits mediate mitogen-activated protein kinase activation by the tyrosine kinase insulin-like growth factor 1 receptor. J Biol Chem. 1995;270:16495–16498.[Abstract/Free Full Text]
  37. Kim S, Izumi Y, Yano M, Hamaguchi A, Miura K, Yamanaka S, Miyazaki H, Iwao H. Angiotensin blockade inhibits activation of mitogen-activated protein kinases in rat balloon-injured artery. Circulation. 1998;97:1731–1737.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Mol. Endocrinol.Home page
L. Hunyady and K. J. Catt
Pleiotropic AT1 Receptor Signaling Pathways Mediating Physiological and Pathogenic Actions of Angiotensin II
Mol. Endocrinol., May 1, 2006; 20(5): 953 - 970.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Haendeler, G. Yin, Y. Hojo, Y. Saito, M. Melaragno, C. Yan, V. K. Sharma, M. Heller, R. Aebersold, and B. C. Berk
GIT1 Mediates Src-dependent Activation of Phospholipase C{gamma} by Angiotensin II and Epidermal Growth Factor
J. Biol. Chem., December 12, 2003; 278(50): 49936 - 49944.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J. Haendeler, J. Hoffmann, R. P. Brandes, A. M. Zeiher, and S. Dimmeler
Hydrogen Peroxide Triggers Nuclear Export of Telomerase Reverse Transcriptase via Src Kinase Family-Dependent Phosphorylation of Tyrosine 707
Mol. Cell. Biol., July 1, 2003; 23(13): 4598 - 4610.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. Dugourd, M. Gervais, P. Corvol, and C. Monnot
Akt Is a Major Downstream Target of PI3-Kinase Involved in Angiotensin II-Induced Proliferation
Hypertension, April 1, 2003; 41(4): 882 - 890.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Suzuki, M. Iwai, H. Nakagami, L. Wu, R. Chen, T. Sugaya, M. Hamada, K. Hiwada, and M. Horiuchi
Role of Angiotensin II-Regulated Apoptosis Through Distinct AT1 and AT2 Receptors in Neointimal Formation
Circulation, August 13, 2002; 106(7): 847 - 853.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
F. Jung, J. Haendeler, J. Hoffmann, A. Reissner, E. Dernbach, A. M. Zeiher, and S. Dimmeler
Hypoxic Induction of the Hypoxia-Inducible Factor Is Mediated via the Adaptor Protein Shc in Endothelial Cells
Circ. Res., July 12, 2002; 91(1): 38 - 45.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
C. Urbich, E. Dernbach, A. M. Zeiher, and S. Dimmeler
Double-Edged Role of Statins in Angiogenesis Signaling
Circ. Res., April 5, 2002; 90(6): 737 - 744.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W. Che, J.-i. Abe, M. Yoshizumi, Q. Huang, M. Glassman, S. Ohta, M. G. Melaragno, V. Poppa, C. Yan, N. Lerner-Marmarosh, et al.
p160 Bcr Mediates Platelet-Derived Growth Factor Activation of Extracellular Signal-Regulated Kinase in Vascular Smooth Muscle Cells
Circulation, September 18, 2001; 104(12): 1399 - 1406.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
B. C. Berk
Vascular Smooth Muscle Growth: Autocrine Growth Mechanisms
Physiol Rev, July 1, 2001; 81(3): 999 - 1030.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
L. Hunyady, Z. Gaborik, G. Vauquelin, and K. J Catt
Review: Structural requirements for signalling and regulation of AT1-receptors
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S16 - S23.
[PDF]


Home page
Circ. Res.Home page
H. Ou, J. Haendeler, M. R. Aebly, L. A. Kelly, B. C. Cholewa, G. Koike, A. Kwitek-Black, H. J. Jacob, B. C. Berk, and J. M. Miano
Retinoic Acid-Induced Tissue Transglutaminase and Apoptosis in Vascular Smooth Muscle Cells
Circ. Res., November 10, 2000; 87(10): 881 - 887.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
U. Schmitz, K. Thommes, I. Beier, W. Wagner, A. Sachinidis, R. Dusing, and H. Vetter
Angiotensin II-induced Stimulation of p21-activated Kinase and c-Jun NH2-terminal Kinase Is Mediated by Rac1 and Nck
J. Biol. Chem., June 15, 2001; 276(25): 22003 - 22010.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
C. Urbich, E. Dernbach, A. M. Zeiher, and S. Dimmeler
Double-Edged Role of Statins in Angiogenesis Signaling
Circ. Res., April 5, 2002; 90(6): 737 - 744.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal